Beaumont Financial Advisors LLC Decreases Stake in Merck & Co., Inc. $MRK

Beaumont Financial Advisors LLC cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 33.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,048 shares of the company’s stock after selling 7,695 shares during the period. Beaumont Financial Advisors LLC’s holdings in Merck & Co., Inc. were worth $1,584,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of MRK. Darwin Wealth Management LLC lifted its stake in Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after acquiring an additional 216 shares during the period. Kilter Group LLC purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Barnes Dennig Private Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares during the period. United Financial Planning Group LLC bought a new stake in shares of Merck & Co., Inc. in the third quarter worth approximately $31,000. Finally, Evolution Wealth Management Inc. purchased a new position in shares of Merck & Co., Inc. during the second quarter valued at approximately $31,000. 76.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Michael Williams sold 5,000 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.91, for a total value of $609,550.00. Following the transaction, the executive vice president directly owned 30,838 shares in the company, valued at approximately $3,759,460.58. The trade was a 13.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 320,176 shares of company stock valued at $38,281,735 in the last ninety days. 0.13% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MRK shares. Wells Fargo & Company increased their price target on Merck & Co., Inc. from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Scotiabank lifted their price objective on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday. Finally, UBS Group raised their target price on Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $127.13.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: European approval expands KEYTRUDA use to a platinum‑resistant ovarian cancer population (PD‑L1 CPS ≥1). This label adds a new, high‑need indication and could incrementally lift oncology sales in Europe if uptake is steady; approval reduces regulatory uncertainty for the combo in that market. Merck granted EU approval of Keytruda combo in ovarian cancer
• Positive Sentiment: European Commission press release confirming KEYTRUDA + paclitaxel ± bevacizumab approval for PD‑L1‑positive, platinum‑resistant recurrent ovarian carcinoma — reinforces the commercial significance of the approval and the company’s oncology momentum in EU markets. European Commission Approves KEYTRUDA combo
• Positive Sentiment: Merck reported strong Phase 3 results for an oral PCSK9 candidate (enlicitide decanoate) — if confirmed through regulatory paths, an oral PCSK9 could be a major commercial opportunity in lipid management and compete with injectables, implying material long‑term upside to cardiovascular franchise revenue. Merck Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Initiation of a pivotal Phase 2b/3 trial for MK‑8748 (Tiespectus) in neovascular AMD shows Merck advancing a novel bispecific Tie2 agonist/VEGF inhibitor into registrational testing — de‑risks a promising ophthalmology program and could add a new specialty product if successful. Merck Announces Initiation of Pivotal Phase 2b/3 Trial
• Positive Sentiment: Royal Bank of Canada assigned an Outperform rating — analyst upgrades/support can buoy sentiment and buying interest, especially when coupled with pipeline news and recent beats. Merck Earns Outperform Rating from RBC
• Neutral Sentiment: Merck released detailed Phase 2 CADENCE data (WINREVAIR) — more granular data helps investors assess clinical profile and commercial potential, but Phase 2 detail typically moves shares less than registrational results unless outcomes are transformational. Merck Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck completed the acquisition of JSR Life Sciences’ chromatography business — broadens manufacturing/service capabilities (note: some headlines refer to Merck KGaA; confirm scope). Strategic but not immediately revenue‑moving for MRK’s core drug sales. Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business
• Neutral Sentiment: Sector commentary: Lilly warned against locking pricing‑deal rules into law, citing innovation risk — a reminder of policy/regulatory uncertainty that can affect the whole pharma sector, including MRK, but it’s not a company‑specific development. Lilly Pushes Back on Making Drug Price Deals Permanent

Merck & Co., Inc. Stock Down 0.2%

MRK opened at $120.62 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a market capitalization of $298.21 billion, a PE ratio of 16.57, a PEG ratio of 2.44 and a beta of 0.26. The firm’s 50 day simple moving average is $117.47 and its two-hundred day simple moving average is $102.80.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.8%. Merck & Co., Inc.’s payout ratio is 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.